title: Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies.
abstract: OBJECTIVE
  Malignant pleural effusion (MPE) means poor prognosis in the majority of cases. Intrapleural Hyperthermic perfusion chemotherapy (HIPEC) looks promising approach for these patients. We aimed to investigate whether cytoreductive surgery followed by HIPEC provides any survival benefit in cases with metastatic MPEs.
  
  
  METHODS
  Between January 2009 and December 2011, 19 patients with metastatic MPEs were treated with HIPEC following surgical interventions such as pleurectomy/decortication and/or lung resection (group 1). Comparison was done with historical control groups consisted of patients who received either talc pleurodesis or pleurectomy/decortication followed by systemic treatment for the management of metastatic MPEs between June 2007 and June 2008 (group 2 and 3). Statistical analyses including overall survival, disease free interval were done for the group comparisons.
  
  
  RESULTS
  Median survival in group 1, 2 and 3 were 15.4, 6, 8 months, respectively. One year survival was 54.7% in group 1 where it was 0.6% and 0.8% in group 2 and 3, respectively. There was no operative mortality. Morbidity was occurred in 1 patient in group 1 (5.3%).
  
  
  CONCLUSIONS
  HIPEC combined with cytoreductive surgery seems to be a promising treatment option for subjects with metastatic MPEs. Further studies are needed for the optimization of HIPEC method, drug of choice, and the best combination therapy for the multimodal treatment.
authors: Gaziantep University, Medical School, Thoracic Surgery Department, Üniversite Bulvarı, Şehitkamil-Gaziantep, Turkey. abaybora@msn.com
authors: Ahmet Feridun
authors: AF
authors: Işık
authors: Maruf
authors: M
authors: Sanlı
authors: Miray
authors: M
authors: Yılmaz
authors: Fatih
authors: F
authors: Meteroğlu
authors: Oner
authors: O
authors: Dikensoy
authors: Alper
authors: A
authors: Sevinç
authors: Celaletdin
authors: C
authors: Camcı
authors: Bülent
authors: B
authors: Tunçözgür
authors: Levent
authors: L
authors: Elbeyli
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D036502:Infusions, Intralesional; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000601:surgery; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D018700:Pleurodesis / Q000379:methods; D011013:Pneumonectomy / Q000379:methods; D012189:Retrospective Studies; D013627:Talc / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013627:Talc; D002945:Cisplatin